Dermatophytic Onychomycosis Treatment Market to Cross USD 9.8 Billion by 2032

Overview

The Global Dermatophytic Onychomycosis Treatment Market is projected to reach USD 9,801 million by 2032, increasing from USD 4,440 million in 2022. The CAGR is expected to be 8.46% during 2023 to 2032. Market growth has been supported by rising infection rates, better awareness, and significant improvements in treatment solutions. These factors have strengthened demand for professional and consumer-focused therapies across multiple regions and healthcare settings, creating a stable and expanding market structure.

The rising prevalence of fungal nail infections has been a primary driver. The increase has been linked to aging populations, higher diabetes incidence, and frequent exposure to humid environments. These conditions have raised infection risks and expanded the patient base. As more individuals experience nail complications, the requirement for effective antifungal solutions has grown. This trend has created sustained demand for advanced therapies that ensure proper management and long-term recovery.

Market expansion has also been supported by improved awareness and early diagnosis. Patients and healthcare providers have become more familiar with common symptoms and the importance of timely treatment. Dermatology clinics have integrated better diagnostic tools that allow precise detection. These advancements have enabled faster and more reliable diagnosis. As awareness improves, patients are more likely to seek medical advice, which continues to support professional treatment uptake.

Advancements in antifungal formulations have further contributed to growth. Newer topical and oral therapies provide better nail penetration and improved cure rates. Research in formulation science has delivered options with fewer side effects and simpler dosage schedules. These improvements have increased patient acceptance and encouraged higher treatment adherence. The ongoing introduction of enhanced products is expected to maintain a positive impact on market performance.

The expansion of distribution channels has strengthened accessibility. Antifungal treatments are now available through pharmacies, hospitals, and online platforms. Digital pharmacies have supported discreet purchasing and easier product comparisons. Growing interest in personal grooming and nail aesthetics has also encouraged treatment adoption. Rising healthcare spending and improved insurance coverage in some regions have further supported market growth by increasing affordability and access to dermatology services.

Key Takeaways

• The market is projected to expand from USD 4,440 million in 2022 to USD 9,801 million by 2032, supported by an 8.46% CAGR.
• Onychomycosis affects nearly 10% of the global population, with 35–40 million Americans impacted, generating sustained demand for treatment solutions.
• Market expansion is strengthened by the availability of water-soluble antifungal formulations, which enhance treatment accessibility and patient compliance across regions.
• New regulatory approvals, including products such as Jublia, are anticipated to elevate therapeutic adoption and contribute significantly to overall market advancement.
• Limited public awareness and inadequate understanding of onychomycosis continue to restrict early diagnosis and reduce the overall pace of market growth.
• Concerns over treatment side effects and drug-related risks remain barriers, dampening patient uptake and negatively influencing market progression.
• Increased investment in research and development for advanced antifungal therapeutics is expected to support innovation and stimulate sustained market demand.
• Government-led awareness programs are contributing to higher diagnosis rates and improved regional market development, particularly in areas with rising healthcare engagement.
• North America remains the leading regional market, supported by a 7.0% CAGR and strengthened by expanded research efforts and clinical trials by major companies.
• Europe is projected to grow at a 5.0% CAGR, supported by awareness campaigns and active participation from countries such as the UK in improving treatment access.
• Asia Pacific demonstrates the fastest growth, driven by developing healthcare systems and initiatives like the introduction of Jublia in Hong Kong, boosting regional opportunities.

Regional Analysis

The North America onychomycosis market is projected to remain the largest regional segment during the forecast period. Steady expansion is expected, supported by a CAGR estimated at up to 7.0% from 2023 to 2032. The United States is anticipated to lead regional growth due to strong industry participation and ongoing research activity. Increased clinical studies focused on new treatment options have strengthened the regional landscape. Pfizer Inc. began clinical trials in 2020 to assess the effectiveness and safety of topical therapies, which reinforced market development in the region.

The rise in diabetes prevalence in the United States has supported market expansion across North America. According to the CDC, nearly one in ten Americans has diabetes, representing about 37.3 million individuals. This growing patient pool increases the risk of fungal nail infections and raises demand for effective treatments. The trend is expected to contribute to market stability over the assessment period. As disease awareness improves and diagnostic rates rise, the regional market is projected to gain sustained momentum throughout the forecast timeline.

The European onychomycosis market is projected to record stable growth, with a forecast CAGR of around 5.0% through 2032. The United Kingdom is expected to play a key role in driving regional performance. Rising awareness initiatives have strengthened patient education and supported treatment adoption. Government-backed campaigns and resources, such as those offered by the British Association of Dermatologists, have increased knowledge about fungal nail infections. These actions are expected to improve early diagnosis and encourage timely treatment, supporting long-term market expansion across Europe.

Asia Pacific is expected to witness the fastest growth in the global onychomycosis market over the forecast period. The rapid expansion is attributed to improvements in healthcare services and strong contributions from emerging economies. Investments in dermatology care and product availability have strengthened regional opportunities. In 2020, Kaken Pharmaceuticals Co. Ltd. introduced Jublia in Hong Kong for dermatophytic mycosis treatment, which supported market penetration. Rising healthcare spending and improved access to clinical products are expected to accelerate regional demand throughout the assessment period.

Segmentation Analysis

The market has been segmented into nail paints and tablets. Nail paints are expected to generate the maximum revenue during the forecast period. This growth is supported by higher adoption of topical solutions and the increasing use of Jublia. A decline in nail paint sales was observed in Japan due to the COVID-19 pandemic. The tablet segment is expected to expand because of rising government initiatives favoring tablets over generics. The continued use of griseofulvin and terbinafine as standard oral therapies is expected to support further tablet uptake.

The market has been categorized into topical and oral routes of administration. The topical segment held the largest share in 2022. Growth has been driven by strong R and D efforts focused on developing advanced topical formulations. Oral medications have shown higher penetration and stronger clinical efficacy. These characteristics have supported segment expansion over the forecast period. Revenue within the oral category declined during 2020 and 2021 because many antifungal oral drugs required prescriptions, which restricted access during pandemic-related healthcare limitations.

The market has been divided into over-the-counter and prescribed types. The prescribed segment has benefited from favorable reimbursement systems, a growing base of podiatrists, and increasing onychomycosis prevalence. Reduced hospital visits and temporary closure of non-emergency outpatient departments affected the segment negatively. The OTC segment dominated overall market revenue. This was supported by growing consumer preference for nail paints and rising sales of ciclopirox for onychomycosis management. The shift toward self-care solutions further strengthened OTC segment performance during the assessment period.

Distribution channels have been classified into hospitals, clinics, retail pharmacies, mail order pharmacies, online sales, drug stores, and other outlets. Retail pharmacies generated the highest revenue because of increased OTC product sales and the rising burden of diabetes and fungal nail infections. Hospital and clinic channels are expected to expand as more individuals seek treatment in formal healthcare settings. Online channels are projected to register significant growth. This trend is supported by the growing adoption of digital pharmacy platforms for medication access and convenience.

Key Market Segments

Based on Product

• Nail Paints
• Tablets

Based on Type

• RX
• OTC

Based on Route of Administration

• Topical
• Oral

Based on Distribution Channel

• Hospitals
• Dermatology and pediatric Clinics
• Retail Pharmacies
• Mail Order Pharmacies and Online Sales
• Drug Stores

Key Players Analysis

The dermatophytic onychomycosis treatment market is shaped by rising disease prevalence and demographic shifts. The high incidence of dermatophytic infections in North America and the expansion of the geriatric population have strengthened the region’s dominance. Growth has been supported by increased awareness, higher treatment adoption, and ongoing efforts to address therapeutic gaps. These conditions have created favorable opportunities for companies aiming to reinforce their global presence and improve product accessibility across major healthcare systems.

Market expansion has also been influenced by strategic acquisitions that strengthened product portfolios and global reach. Corporate consolidation has been used to enhance competitiveness in foreign markets and accelerate innovation. A notable example is Sanofi’s acquisition of Kadmon Holdings in November 2021. This transaction, completed through a subsidiary merger under Delaware’s General Corporation Law, enabled Kadmon to operate as the surviving corporation while becoming part of Sanofi’s broader structure. The integration was intended to support pipeline growth and improve long-term commercial performance.

Competitive positioning has been defined by product performance, revenue contribution, and therapeutic efficacy. Bausch Health secured a leading role due to strong sales of Jublia, which generated around USD 110 million in 2019 and demonstrated a superior cure rate compared to other topical lacquers. Pfizer followed with rising demand for Kerydin. However, both companies are projected to face downward pressure on market share due to patent expiration and economic disruptions linked to COVID-19. These dynamics are expected to reshape competitive strategies across the treatment landscape.

Market Key Players

• Bausch Health Companies
• Celtic Pharma
• Galderma S.A.
• Johnson & Johnson
• Anacor pharmaceuticals Inc.
• Pfizer Inc.
• GlaxoSmithKline Plc
• Novartis AG
• Topica Pharmaceuticals Inc.
• Bayer AG
• Moberg Pharma AB
• Allergen Inc.
• Cipla Ltd
• Reddy’s Laboratories Ltd
• Other Key Players

Conclusion

The dermatophytic onychomycosis treatment market is expected to show steady and sustained growth over the coming years. This progress is supported by rising infection cases, better diagnosis, and improved treatment options that offer higher patient comfort and stronger therapeutic outcomes. Growth is further reinforced by expanding access to both prescription and over-the-counter products through hospitals, clinics, and online channels. Continued investment in research is expected to produce safer and more effective antifungal solutions, improving patient adoption across regions. With strong participation from major companies and increasing awareness among consumers, the market is projected to maintain a positive and stable outlook.

Get in Touch with Us:
Market.us (Powered By Prudour Pvt. Ltd.)
Address: 420 Lexington Avenue, Suite 300, New York City, NY 10170, United States.
Contact No: +1 718 874 1545 (International), +91 78878 22626 (Asia).
Email: [email protected]